

# CITATION REPORT

List of articles citing

Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma

DOI: 10.1371/journal.pone.0052398  
PLoS ONE, 2012, 7, e52398.

**Source:** <https://exaly.com/paper-pdf/86988805/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 23 | Noninvasive visualization of tumor growth in a human colorectal liver metastases xenograft model using bioluminescence in vivo imaging. <i>Journal of Surgical Research</i> , <b>2013</b> , 185, 143-51 | 2.5  | 17        |
| 22 | Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model. <i>Blood Cancer Journal</i> , <b>2014</b> , 4, e217  | 7    | 35        |
| 21 | A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo. <i>MAbs</i> , <b>2014</b> , 6, 297-308   | 6.6  | 19        |
| 20 | Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. <i>Nature Communications</i> , <b>2015</b> , 6, 8983  | 17.4 | 232       |
| 19 | Association of colorectal cancer with pathogenic Escherichia coli: Focus on mechanisms using optical imaging. <i>World Journal of Clinical Oncology</i> , <b>2016</b> , 7, 293-301                      | 2.5  | 28        |
| 18 | The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155087  | 3.7  | 11        |
| 17 | Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice. <i>Molecular Therapy - Oncolytics</i> , <b>2016</b> , 3, 16032  | 6.4  | 23        |
| 16 | In vivo fluorescence imaging to assess early therapeutic response to tumor progression in a xenograft cancer model. <i>Biotechnology and Bioprocess Engineering</i> , <b>2016</b> , 21, 567-572         | 3.1  | 1         |
| 15 | MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties. <i>BMC Cancer</i> , <b>2016</b> , 16, 115                                    | 4.8  | 15        |
| 14 | CD38 as a PET Imaging Target in Lung Cancer. <i>Molecular Pharmaceutics</i> , <b>2017</b> , 14, 2400-2406   | 5.6  | 17        |
| 13 | Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS. <i>Leukemia</i> , <b>2017</b> , 31, 922-933                        | 10.7 | 13        |
| 12 | The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells. <i>Oncotarget</i> , <b>2017</b> , 8, 111931-111942                          | 3.3  | 41        |
| 11 | JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. <i>Leukemia</i> , <b>2018</b> , 32, 736-743  | 14.7 | 39        |
| 10 | The genetic landscape of 5T models for multiple myeloma. <i>Scientific Reports</i> , <b>2018</b> , 8, 15030   | 4.9  | 10        |
| 9  | Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific V $\beta$ T cell families. <b>2019</b> , 7, 301  |      | 2         |
| 8  | Persistent STAT5 activation reprograms the epigenetic landscape in CD4 T cells to drive polyfunctionality and antitumor immunity. <i>Science Immunology</i> , <b>2020</b> , 5,                          | 28   | 13        |
| 7  | Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn. <i>Experimental Hematology</i> , <b>2021</b> , 93, 61-69.e4                               | 3.1  | 0         |

|   |   |      |    |
|---|---|------|----|
| 6 | Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression. <i>Leukemia</i> , <b>2021</b> ,   | 10.7 | 5  |
| 5 | Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 4375-90  | 15.9 | 67 |
| 4 | Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2R(hull) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies. <i>PLoS ONE</i> , <b>2013</b> , 8, e79939 | 3.7  | 19 |
| 3 | Junctional Adhesion Molecule-C expression specifies a CD138 <sup>low</sup> /neg multiple myeloma cell population in mice and humans. <i>Blood Advances</i> , <b>2021</b> ,  | 7.8  | 1  |
| 2 | Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens.. <b>2022</b> , 10,                   |      | 1  |
| 1 | Preclinical Osteoimmuno-Oncology Models to Study Effects of Immunotherapies on Bone Metastasis. <b>2022</b> , 167-209   |      |    |